StockData

Lipocine vs NRX Pharmaceuticals

LPCN and NRXP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LPCN and NRXP compare

NRX Pharmaceuticals is the larger company, worth 8.0 times as much as Lipocine ($106M against $13.2M).

NRX Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −692% compared with −755% at Lipocine.

Lipocine scores higher on the StockData Score (9 against 0 for NRX Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLPCNNRXP
Size and price
Market cap$13.2M$106M
Share price$1.60$2.45
Change, 1 year−44.3%−1.6%
Change, 5 years−91.7%−96.4%
Beta (5Y)−0.381.15
Employees1429
StockData Score
Total score9 (better)0
Valuation score3 (better)0
Growth score1 (better)0
Performance score00
Health score5 (better)0
Dividend score00
Valuation
P/S8.4× (better)31.3×
P/B0.6×–
Fair value$2.64–
Margin of safety39.3%–
Growth
Revenue growth (TTM)−62.7%–
Profitability
Gross margin–46.6%
Operating margin−801%−586% (better)
Net margin−755%−692% (better)
Return on equity−60.9%–
Financial health
Debt / equity0.00–
Interest coverage–−17.4×
Current ratio11.48 (better)0.86
Altman Z-score−9.43 (better)−13.45
Piotroski F-score15 (better)
Dividends and buybacks
Buyback yield−123%–
Shareholder yield−123%0.00% (better)
Ownership
Held by institutions36.2%26.9%
Held by insiders9.0%15.6%
Insider net buying, 12 months$596K–
Short interest, % of float4.3%28.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.